// App-Quantinova.ai

: ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Researchers

Presenter

  • Olalekan O. Oluwole

Principal Investigators

  • Saad S. Kenderian

  • Parveen Shiraz

  • Reem Karmali

  • Ran Reshef

  • Philip L. McCarthy

  • Nilanjan Ghosh

  • Aleksandr Lazaryan

  • Simone Filosto

  • Soumya Poddar

  • Daqin Mao

  • Andrew Peng

  • Adrian Kilcoyne

  • Myrna Nahas

  • Sattva S. Neelapu

Medical Centers

  • Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston, TX

  • Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H.Lee Moffitt Cancer Center and Research Institute, Tampa, FL

  • Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL

  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN

  • Vanderbilt University Medical Center, Nashville, TN

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY

  • Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC

  • Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA

  • Blood and Marrow Transplantation Program, Columbia University, New York, NY

Locations

  • United States

Companies

  • Kite Pharma, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

  • Solid malignancies

Biomarkers

  • Coxsackie Virus And Adenovirus Receptor

  • Twist-related protein 1

Drug/Treatment

  • Axicabtagene ciloleucel

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

  • KB003

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Pharmacokinetics

  • Cohort

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved